PURPOSE: Failure to gefitinib is generally believed to be associated with cross-resistance to
other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here we report …

Aberrant activation of the epidermal growth factor receptor (EGFR) is a driving force for
cancer growth in a subgroup of non-small cell lung cancer patients. These patients can be …

Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …

The activity of erlotinib after gefitinib failure in non-small cell lung cancer patients with all
four favorable clinical factors including female, never smoker, Asian, and adenocarcinoma …

Introduction First-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
treatment of advanced non–small-cell lung cancer with EGFR-activating mutations improves …

Opinion statement Patients whose tumors harbor somatic-activating mutations within the
epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of …

Epidermal growth factor receptor (EGFR) gene mutations identify a molecularly defined
subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to …

Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here,
we present an update on new controversies and conclusions regarding the disease …

Despite recent advances in the systemic therapy of non-small-cell lung cancer (NSCLC), the
prognosis for stage IV disease remains poor. The discovery of targetable mutations has led …

Discovery of sensitizing mutations in epidermal growth factor receptor (EGFR) and the
subsequent development of EGFR tyrosine kinase inhibitors (TKIs) have substantially …